MOTS-c is one of a small class of peptides encoded inside the mitochondrial genome rather than the nuclear DNA that specifies almost every other human protein. The published record describes it as a 16-amino-acid regulator of metabolism first reported in 2015, but that record sits almost entirely at the cell-culture and animal-model stage, and MOTS-c holds no FDA approval for any therapeutic use.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide first reported in 2015, studied mainly in cell and animal models as a metabolic regulator and not approved by the FDA for any therapeutic use.
The name is a map to the peptide's genomic address, not a description of what it does. It expands to Mitochondrial Open reading frame of the Twelve S type-c, a label that had to be paired with separate laboratory work before anyone knew the molecule was biologically active.
MOTS-c expands to Mitochondrial Open reading frame of the Twelve S type-c, a name that describes the peptide's origin inside the mitochondrial 12S ribosomal RNA gene rather than any biological activity.
MOTS-c is small even by peptide standards, and that size is a defining structural trait. Its mature human form runs just 16 amino acids against the 51 residues of insulin, small enough to move between subcellular compartments and to be built readily by solid-phase peptide synthesis.
The mature human MOTS-c peptide is a 16-amino-acid chain with the sequence MRWQEMGYIFYPRKLR and a molecular weight near 2 kilodaltons, translated using the mitochondrial genetic code.
The single most important fact about MOTS-c's origin is its address: mitochondrial DNA, not the nuclear genome. Human mitochondria carry a circular chromosome of roughly 16,500 base pairs holding 37 genes, and the MOTS-c reading frame is nested inside one of its two ribosomal RNA genes, the 12S gene whose main product is structural RNA rather than a protein.
MOTS-c is encoded within the 12S ribosomal RNA gene of the roughly 16,500-base-pair circular mitochondrial chromosome, not in the nuclear genome.
A mitochondrial-derived peptide is a small protein product coded in the mitochondrial genome rather than the nuclear one, a category that overturned the textbook assumption that mtDNA encodes only 13 proteins, all of them respiratory-chain components. Humanin, hidden in the 16S ribosomal RNA gene, was the first member characterized; MOTS-c belongs to the same family but sits in the 12S gene and reads as a systemic metabolic signal rather than a local protective factor.
| Trait | Humanin | MOTS-c |
|---|---|---|
| Encoding gene | 16S rRNA gene | 12S rRNA gene |
| Position in class | first MDP characterized | reported 2015 |
| Reported primary role | cytoprotective, neuroprotective | metabolic regulation, insulin sensitivity |
| Reported mode of action | local protective factor | circulating, hormone-like signal |
Mitochondrial-derived peptides are encoded in mitochondrial rather than nuclear DNA, and MOTS-c is the 12S ribosomal RNA gene member reported to act as a systemic, hormone-like metabolic signal.
MOTS-c entered the peer-reviewed literature in 2015, the product of a deliberate hunt for coding potential hidden in the mitochondrial genome rather than an accidental find. The path from a computed reading frame to a metabolic peptide ran through synthesis and animal testing, so from the outset the evidence was preclinical, establishing biological plausibility rather than any human benefit.
MOTS-c was first reported in a 2015 peer-reviewed study that identified it through a bioinformatic search of the mitochondrial 12S rRNA gene and confirmed its metabolic effects in cell and mouse models.
The role most consistently attributed to MOTS-c is metabolic regulation through activation of AMP-activated protein kinase, or AMPK, the master cellular sensor that switches on energy-generating pathways when fuel runs short. Reported downstream effects include greater glucose uptake, improved insulin sensitivity, and a shift toward more efficient fuel handling, most pronounced in models of metabolic stress. These findings come overwhelmingly from cell-culture and rodent work, so they stand as reproducible research observations rather than proven human actions.
MOTS-c is primarily characterized as a metabolic regulator that activates AMP-activated protein kinase (AMPK) to promote glucose uptake and insulin sensitivity, an effect demonstrated in cell-culture and rodent models rather than human trials.
MOTS-c behaves as a stress-responsive signal, rising under the conditions that strain a cell's energy balance. Because it is detectable in skeletal muscle and circulating in blood, the literature reads its response as systemic and hormone-like rather than confined to a single cell, though these associations remain largely observational.
MOTS-c levels rise under metabolic stressors including exercise, fasting, caloric restriction, and glucose deprivation, while several reports describe its decline with advancing age.
A striking feature of MOTS-c is that its location inside the cell is dynamic and tied to its job. At baseline it associates with the mitochondria and cytoplasm; under metabolic or oxidative stress a fraction relocates to the nucleus, and that stress-dependent move is the mechanistic heart of its reported gene-regulatory role.
Under metabolic or oxidative stress MOTS-c translocates from the mitochondria and cytoplasm to the nucleus, where it associates with stress-responsive transcription factors to activate antioxidant and metabolic gene programs.
MOTS-c is an investigational research peptide and nothing more settled than that. It carries no FDA approval, or approval from any comparable agency, for treating, preventing, or curing any disease, and its published evidence sits overwhelmingly at the preclinical, cell-and-animal stage. Material sold outside formally regulated research channels carries the ordinary hazards of unapproved substances: uncertain purity, unverified dosing, unknown long-term safety, and no medical oversight.
MOTS-c is an investigational research peptide with no FDA approval for any disease, supported almost entirely by preclinical cell and animal evidence rather than controlled human clinical trials.
Educational use only. This article describes what the published scientific and clinical literature reports about MOTS-c. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
